News

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

Psychiatric Times celebrates 40 years of advancing mental health care, offering insights, news, and community for psychiatric professionals. Join us in 2026!

Explore innovative solutions to combat burnout in health care, including coaching, psychedelics, and addressing administrative harm for lasting change.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

American psychiatry struggles with understanding psychopathology, emphasizing the need to return to its roots for accurate diagnosis and effective treatment.

What were the top psychiatric hits of 2025?

Psychiatry needs compassionate, culturally competent leaders to address mental health challenges and promote innovative solutions for a healthier future.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

A critical shortage of IV lorazepam disrupts psychiatric care, particularly for patients with catatonia, highlighting broader pharmaceutical supply chain issues.

A recent survey reveals that 13% of US youth use generative AI for mental health advice, highlighting its perceived benefits and potential risks.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Explore the complexities of mental illness, its definitions, and the limitations of current psychiatric diagnosis in understanding true psychopathology.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Explore impactful ways to contribute on Giving Tuesday, supporting mental health organizations dedicated to making a difference in psychiatry.

Meta-analysis identifies 2 antidepressants that separate from placebo and other antidepressants in relieving negative symptoms of schizophrenia

Adolescent cannabis use surges in Oklahoma, raising public health concerns amid rising THC potency and permissive regulations.

Discover the positive shifts in psychiatry, from youth mental health improvements to innovative treatment technologies, amidst current challenges.

What are the most important psychiatric advancements and insights from 2025? Share with us!

Read discussion of bromism, with case studies and background on bromine.

ChatGPT's rapid rise sparks debate on its profound impact, blending remarkable capabilities with alarming risks, as society grapples with AI's future.

Explore the importance of gratitude in psychiatry, addressing challenges, stigma, and the pursuit of mental health improvement in communities.

Explore updates from November 2025, including AI, drug updates, and more.

Check out the pipeline updates from November!

"When the spade sinks into gravelly ground: My father, digging. I look down..."

Tiffani Bell-Washington, MD, MPH shares insights on compassionate lifestyle changes for adolescents facing obesity, emphasizing collaboration and individualized care strategies.

In this CME article, explore effective strategies for assessing and preventing suicide risk in patients with bipolar disorder, including interdisciplinary approaches and evidence-based interventions.

Lithium significantly reduces suicidal ideation and attempts in bipolar and major depressive disorder patients, enhancing long-term treatment outcomes.

Otsuka Pharmaceutical submits a new drug application for centanafadine for treatment of ADHD, showing significant efficacy across all age groups.